Investor Presentaiton
Advancing Guardant360 TissueNext with
Al-powered digital pathology
INVESTOR 20
DAY 23
GUARDANT 360 TissueNext
GUARDANT
GALAXY PD-L1
Only tissue CGP panel
with an Al-powered
scoring algorithm that
improves PD-L1
detection by >20% in
NSCLC1
Now validated for
multiple cancers²
Covered by Medicare
for all advanced solid
tumors³
GUARDANT™
Al = Artificial Intelligence. *Compared to manual pathologist interpretation in the most challenging cases in NSCLC. Including breast, colorectal, gastric, hepatobiliary, lung, pancreatic, prostate, and
urothelial cancers. 1. https://www.ejcancer.com/article/S0959-8049(22)00215-5/fulltext. 2. https://www.annalsofoncology.org/article/S0923-7534(21)01146-7/fulltext Important Note: Guardant360
TissueNext and Guardant Galaxy PD-L1 tests were developed, and their performance characteristics determined, by Lunit. These tests have not been cleared or approved by the US FDA. 3. Coverage
limited to LFS for PDL-1 test.
53
53View entire presentation